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CASE REPORTS
Case 1
In September 2012, a 74-year-old nonsmoker man was admit-
ted to our hospital with dyspnea and general health degra-
dation. A tumor in the upper lobe of the right lung, bilateral 
mediastinal lymphadenopathies, and a right pleural effusion 
were evident on abdominal computed tomography (CT) scan 
(Fig. 1B). Both pleural effusion and lung biopsies contained 
tumor cells presenting the p.L858R EGFR (exon 21) muta-
tion. This alteration was also detected in the plasma sample 
collected before treatment (Fig. 1A).
Two months after tyrosine kinase inhibitor (TKI) treat-
ment initiation, the patient presented a significant general 
health degradation and weight loss (7 kg). No significant tumor 
reduction was seen on the CT scan, and a pleural effusion was 
still present (Fig. 1C). The activating EGFR mutation was 
present at a stable level in plasma. In addition, the p.T790M 
mutation (not detected in the primary tumor and in the pre-
vious plasma samples) was detected in the last sample (Fig. 
1A). The patient experienced progressive pleural effusion and 
important clinical deterioration and died in December 2012.
Case 2
A 63-year-old never-smoker woman was presented with cough 
and weight loss in August 2012. The initial CT scan showed a 
large tumor in the upper lobe of the right lung (Fig. 2B) and a 
single bone metastasis. Lung biopsies were found to contain 
thyroid transcription factor-1 positive adenocarcinoma cells, 
harboring an exon 19 deletion of the EGFR gene. This altera-
tion was also detected in the plasma (Fig. 2A).
This patient was treated with an EGFR TKI. After 1 
month, the patient reported improvement in both cough and 
weight. Two months after starting treatment, CT demonstrated 
a significant shrinkage of the lung tumor (50% objective 
response; Fig. 2C), and the EGFR mutation remained unde-
tectable in plasma during 6 months (Fig. 2A).
A progression of the tumor was seen on the control 
CT scan performed 11 months following treatment initiation 
(Fig. 2D). The EGFR-activating mutation simultaneously 
reappeared in the plasma.
DISCUSSION
Liquid biopsies have recently emerged as an important source 
of biomarkers in clinical oncology. For instance, tumor 
cells circulating in blood can be used to determine the ALK 
(Anaplastic Lymphoma Kinase) status of patients with lung 
cancer,1 and EGFR alterations can be detected in cell-free 
circulating tumor DNA of patients before TKI treatment.2–4 
Bai et al.5 recently demonstrated an effect of neoadjuvant 
chemotherapy on change in EGFR mutation in plasma sam-
ples. We present here the results obtained during follow-up 
of two patients during TKI treatment. Although in patient 1, 
who did not respond to TKI treatment, the EGFR mutation 
was detected at similar levels in all plasma samples, in patient 
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FIGURE 1. A, Detection of EGFR alterations in the plasma 
of patient 1. DNA was extracted from plasma, and EGFR 
alterations (p.L858R ■; p.T790M □) were detected by 
 allele-specific amplification using the Therascreen RGQ EGFR 
kit as previously described.4 The fraction of mutated copies 
of the EGFR gene was determined using a standard curve 
generated using serial dilutions of mutated DNA extracted 
from control slides of formalin-fixed paraffin-embedded cell 
lines block with defined ratios of mutant alleles (Horizon 
Discovery, Cambridge, United Kingdom) into wild-type DNA. 
Chest computed tomography images at baseline (B) and after 
3 months of tyrosine kinase inhibitor treatment (C).
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2 the EGFR mutation disappeared from plasma DNA during 
treatment response and reappeared at progression.
our data suggest that the disappearance of circulating 
EGFR-mutated DNA may be a marker of TKI response. Few 
studies have attempted to detect EGFR mutations in plasma 
samples from non–small-cell lung cancer patients under targeted 
therapy or during follow-up period. But the techniques used 
(microfluidic digital polymerase chain reaction6;  allele-specific 
arrayed primer extension),7 which are time consuming and 
require expensive hardware, are not suitable for use in a routine 
clinical biochemistry or DNA diagnosis laboratory. In a recent 
report, whole exome sequencing of plasma DNA was used to 
assess tumor dynamics of patient with lung tumor.8 But this 
very powerful technique is not yet compatible with routine clini-
cal practice. In our study, DNA extraction and EGFR mutation 
detection using the approved and efficient9 Therascreen EGFR 
RGQ kit (Qiagen, Hilden, Germany ) can be performed within 
3 hours. We previously described that this procedure allowed 
us to detect activating EGFR mutations in plasma of advanced 
non–small-cell lung cancer patients before TKI treatment with a 
sensitivity of 94.7% and a specificity of 100%.4
Although promising, our data do not allow any reduction 
or change in the use of radiological examinations or even in the 
rebiopsy interest at the present time. But following confirma-
tion of our results on a larger cohort, analysis of plasma DNA 
could turn out to be a useful biomarker for real-time monitor-
ing of patients receiving EGFR TKI in routine clinical practice.
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FIGURE 2. A, Detection of EGFR alterations in the plasma of 
patient 2. DNA was extracted from plasma, and EGFR altera-
tions (Del19 ■; p.T790M □) were detected and quantified as 
described in Figure 1. Chest computed tomography images 
at baseline (B) and after 6 months (C) and 11 months (D) of 
tyrosine kinase inhibitor treatment.
